Business Description
Santhera Pharmaceuticals Holding AG
ISIN : CH1276028821
Total Employee Number:
99Description
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.46 | |||||
Equity-to-Asset | -0.08 | |||||
Debt-to-Equity | -4.14 | |||||
Debt-to-EBITDA | -1.54 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -5.62 | |||||
Beneish M-Score | -1.06 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 69.1 | |||||
3-Year EBITDA Growth Rate | 28.4 | |||||
3-Year EPS without NRI Growth Rate | 30.5 | |||||
3-Year FCF Growth Rate | 21.6 | |||||
3-Year Book Growth Rate | 49 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 18.78 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 17.86 | |||||
9-Day RSI | 32.05 | |||||
14-Day RSI | 38.13 | |||||
3-1 Month Momentum % | -5.82 | |||||
6-1 Month Momentum % | 21.21 | |||||
12-1 Month Momentum % | 25.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.29 | |||||
Quick Ratio | 0.89 | |||||
Cash Ratio | 0.36 | |||||
Days Inventory | 134.25 | |||||
Days Sales Outstanding | 45.65 | |||||
Days Payable | 85.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -26.7 | |||||
Shareholder Yield % | -5.58 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 19.66 | |||||
Operating Margin % | -48.73 | |||||
Net Margin % | -63.79 | |||||
EBITDA Margin % | -41.22 | |||||
FCF Margin % | -45.11 | |||||
OCF Margin % | -45.04 | |||||
ROE % | -1109 | |||||
ROA % | -34.24 | |||||
ROIC % | -34.61 | |||||
3-Year ROIIC % | 152.35 | |||||
ROC (Joel Greenblatt) % | -1632.11 | |||||
ROCE % | -42.41 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 196.22 | |||||
PS Ratio | 2.51 | |||||
EV-to-EBIT | -6.56 | |||||
EV-to-Forward-EBIT | 14.75 | |||||
EV-to-EBITDA | -7.73 | |||||
EV-to-Forward-EBITDA | 12.48 | |||||
EV-to-Revenue | 3.19 | |||||
EV-to-Forward-Revenue | 2.36 | |||||
EV-to-FCF | -7.07 | |||||
Price-to-GF-Value | 0.64 | |||||
Earnings Yield (Greenblatt) % | -15.24 | |||||
FCF Yield % | -15.86 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Santhera Pharmaceuticals Holding AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 77.185 | ||
| EPS (TTM) (CHF) | -3.78 | ||
| Beta | 0.5367 | ||
| 3-Year Sharpe Ratio | 0.01 | ||
| 3-Year Sortino Ratio | 0.01 | ||
| Volatility % | 52.72 | ||
| 14-Day RSI | 38.13 | ||
| 14-Day ATR (CHF) | 0.53705 | ||
| 20-Day SMA (CHF) | 15.6745 | ||
| 12-1 Month Momentum % | 25.83 | ||
| 52-Week Range (CHF) | 9.425 - 18.8 | ||
| Shares Outstanding (Mil) | 14.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Santhera Pharmaceuticals Holding AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Santhera Pharmaceuticals Holding AG Stock Events
| Event | Date | Price (CHF) | ||
|---|---|---|---|---|
| 0.1:1 Stock Split | 2023-07-03 | 8.24 (+0.00%) |
Show
Entries
Santhera Pharmaceuticals Holding AG Frequently Asked Questions
What is Santhera Pharmaceuticals Holding AG(CHIX:SANNz)'s stock price today?
The current price of CHIX:SANNz is CHF14.84. The 52 week high of CHIX:SANNz is CHF18.80 and 52 week low is CHF9.43.
When is next earnings date of Santhera Pharmaceuticals Holding AG(CHIX:SANNz)?
The next earnings date of Santhera Pharmaceuticals Holding AG(CHIX:SANNz) is .
Does Santhera Pharmaceuticals Holding AG(CHIX:SANNz) pay dividends? If so, how much?
Santhera Pharmaceuticals Holding AG(CHIX:SANNz) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Santhera Pharmaceuticals Holding AG
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers